Free Trial
NASDAQ:AVTE

Aerovate Therapeutics (AVTE) Stock Price, News & Analysis

Aerovate Therapeutics logo
$6.89 -0.30 (-4.17%)
As of 08/1/2025

About Aerovate Therapeutics Stock (NASDAQ:AVTE)

Key Stats

Today's Range
$6.87
$7.56
50-Day Range
$6.76
$11.14
52-Week Range
$56.35
$105.00
Volume
143,073 shs
Average Volume
12,438 shs
Market Capitalization
$199.71 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive AVTE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aerovate Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AVTE Stock News Headlines

[Warning] Buffett Indicator hits new All-Time-High
Warren Buffett has leaned on one key indicator for decades—and it just hit an all-time high. That’s not bullish for stocks. In fact, the last three times this happened, a major market pullback followed… and gold entered a decade-long bull run. If history’s any guide, the smartest move today could be positioning in gold—specifically, a handful of high-potential developers.
See More Headlines

AVTE Stock Analysis - Frequently Asked Questions

Aerovate Therapeutics' stock was trading at $92.75 at the beginning of 2025. Since then, AVTE shares have decreased by 92.6% and is now trading at $6.89.

Aerovate Therapeutics, Inc. (NASDAQ:AVTE) released its earnings results on Friday, April, 25th. The company reported ($3.15) earnings per share for the quarter, beating analysts' consensus estimates of ($10.50) by $7.35.

Aerovate Therapeutics shares reverse split before market open on Tuesday, April 29th 2025.A 1-35 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Monday, April 28th 2025. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Aerovate Therapeutics (AVTE) raised $100 million in an IPO on Wednesday, June 30th 2021. The company issued 7,150,000 shares at $13.00-$15.00 per share.

Shares of AVTE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Aerovate Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Palo Alto Networks (PANW), Tesla (TSLA) and JPMorgan Chase & Co. (JPM).

Company Calendar

Last Earnings
4/25/2025
Today
8/02/2025
Next Earnings (Estimated)
8/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:AVTE
CIK
1798749
Fax
N/A
Employees
20
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($1.70)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$75.52 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-90.19%
Return on Assets
-77.47%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
8.78
Quick Ratio
8.78

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.96 per share
Price / Book
1.74

Miscellaneous

Outstanding Shares
28,985,000
Free Float
21,685,000
Market Cap
$199.71 million
Optionable
Optionable
Beta
0.95
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:AVTE) was last updated on 8/2/2025 by MarketBeat.com Staff
From Our Partners